Investopedia: Agilent Grinding Through Challenging Market Conditions

It may not look like it on the basis of the last few quarters, but Agilent (NYSE: A ) is getting better. Weakness in multiple test and mea...

Seeking Alpha: Can Tiny Synergetics See A Big Surge?

Having made some solid capital gains from various ophthalmology and niche med-tech companies in the past, I looked into Synergetics ( SURG ...

Investopedia: Becton Dickinson Already Priced For Excellence

It's pretty rare to see an “Underperform” rating on a med-tech stock these days, but Becton Dickinson (NYSE: BDX ) carries more than Jo...

Investopedia: The Street Has Caught Covidien

For most of 2012 and 2013, Covidien (NYSE: COV ) was the not-so-little med-tech that could. In an environment were companies like Johnson ...

Investopedia: Roche Delivering Leverage, But Needs Diversification

These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq: RHHBY ), as the company continues to see double-digit growth ac...

Investopedia: Abbott Labs Making Progress On Margins, Now It Needs More Growth

Since making the split from AbbVie (Nasdaq: ABBV ), Abbott Labs (NYSE: ABT ) has had something of a mixed debut. The stock has not only l...

Investopedia: Abbott Adds Two Promising Products

Abbott Labs (NYSE: ABT ) has never been shy about using M&A to build its business, and it was generally assumed that more deals would ...

MassDevice: Diabetes: The Path To An Artificial Pancreas Looks A Little More Reasonable

There are more than a few similarities between the idea of building an artificial pancreas and finding the Holy Grail – everybody agrees t...

MassDevice: Can C.R. Bard Use A Windfall To Reignite Growth?

C.R. Bard (NYSE: BCR ) has a problem; specifically, a growth problem. While the company has #1 or #2 market share in markets that make up...

MassDevices: Boston Scientific May Finally Be On The Right Path Again

It feels like Boston Scientific (NYSE: BSX ) has spent the majority of the past decade in a perpetual limbo of ineffectual turnaround. Th...

Investopedia: It Gets A Little Harder From Here For Covidien

Covidien (NYSE: COV ) has been one of the strongest large-cap med-tech stories over the past year or so. At a time when companies like Johns...

Investopedia: Pharma Is Doing All The Pulling For Johnson & Johnson

While other healthcare companies including Covidien (NYSE: COV ) and Abbott (NYSE: ABT ) have seen fit to split their drug and device busi...